Trials / Terminated
TerminatedNCT01090310
Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis
A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This extension study will assess the safety and efficacy of AIN457 versus placebo for maintaining uveitis suppression when reducing systemic immunosuppression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AIN457 | AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake |
| DRUG | Placebo | Matching placebo to AIN457 |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-03-19
- Last updated
- 2016-01-14
- Results posted
- 2016-01-14
Locations
35 sites across 8 countries: United States, Brazil, Germany, India, Israel, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT01090310. Inclusion in this directory is not an endorsement.